Albert Sabin a vaccine to prevent or mitigate the illness. The Sabin vaccine is an oral vaccine containing weakened forms of strains of polio viruses. In 1955, Salk's "killed" vaccine was released for use. It was effective in preventing most of the complications of polio, but did not prevent the initial intestinal infection. The Sabin vaccine is easier to give than the earlier vaccine developed by Salk in 1954, and its effects last longer. Sabin first tested his live attenuated oral vaccine at the Chillicothe Ohio Reformatory in late 1954. From 1956–1960, he worked with Russian colleagues to perfect the oral vaccine
HPV vaccine at the University of Queensland have been accorded priority under U.S. patent law for the invention of the HPV vaccine's basis, the VLPs. In 2006, the FDA approved the first preventive HPV vaccine, marketed by Merck & Co. under the trade name Gardasil. According to a Merck press release, in the second quarter of 2007, it had been approved in 80 countries, many under fast-track or expedited review. Early in 2007, GlaxoSmithKline filed for approval in the United States for a similar preventive HPV vaccine, known as Cervarix. In June 2007 this vaccine was licensed in Australia, and it was